JP2022523919A5 - - Google Patents
Info
- Publication number
- JP2022523919A5 JP2022523919A5 JP2021545944A JP2021545944A JP2022523919A5 JP 2022523919 A5 JP2022523919 A5 JP 2022523919A5 JP 2021545944 A JP2021545944 A JP 2021545944A JP 2021545944 A JP2021545944 A JP 2021545944A JP 2022523919 A5 JP2022523919 A5 JP 2022523919A5
- Authority
- JP
- Japan
- Prior art keywords
- fenofibrate
- subject
- kaempferol
- disease
- parkinson
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962801271P | 2019-02-05 | 2019-02-05 | |
| US62/801,271 | 2019-02-05 | ||
| PCT/US2020/016820 WO2020163493A2 (en) | 2019-02-05 | 2020-02-05 | Materials and methods for treating a neurodegenerative disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022523919A JP2022523919A (ja) | 2022-04-27 |
| JP2022523919A5 true JP2022523919A5 (https=) | 2023-02-14 |
Family
ID=71947875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545944A Pending JP2022523919A (ja) | 2019-02-05 | 2020-02-05 | 神経変性疾患を治療するための物質および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220401404A1 (https=) |
| EP (1) | EP3930711A4 (https=) |
| JP (1) | JP2022523919A (https=) |
| CN (1) | CN114007607A (https=) |
| AU (1) | AU2020219140A1 (https=) |
| BR (1) | BR112021015466A2 (https=) |
| CA (1) | CA3129050A1 (https=) |
| MX (1) | MX2021009413A (https=) |
| WO (1) | WO2020163493A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021022270A2 (pt) * | 2019-05-06 | 2022-01-11 | Univ California | Materiais e métodos para tratar degeneração macular relacionada à idade |
| CN115429788B (zh) * | 2022-10-24 | 2023-11-21 | 上海中医药大学附属岳阳中西医结合医院 | 一种治疗脱髓鞘疾病的药物及应用 |
| CN119454686A (zh) * | 2024-08-06 | 2025-02-18 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | 山柰酚或含有山柰酚的组合物在制备治疗和/或缓解多发性硬化症药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1850840A2 (en) | 2005-01-13 | 2007-11-07 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| AU2007299920A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | PPAR Mediated Modulation of Neurogenesis |
| US20120082659A1 (en) * | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
| WO2009147009A2 (en) * | 2008-06-06 | 2009-12-10 | Nicox S.A. | Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug |
| US20130252924A1 (en) * | 2010-11-11 | 2013-09-26 | Akron Molecules Gmbh | Compounds and Methods for Treating Pain |
| WO2013049621A1 (en) * | 2011-09-29 | 2013-04-04 | The Board Of Regents Of The University Of Oklahoma | Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof |
| CN105636582A (zh) * | 2013-09-18 | 2016-06-01 | 乔治城大学 | 用非诺贝特及其类似物治疗神经退行性疾病 |
| CN109069450A (zh) * | 2016-02-05 | 2018-12-21 | 法奈克斯公司 | 神经障碍的新的组合疗法 |
-
2020
- 2020-02-05 JP JP2021545944A patent/JP2022523919A/ja active Pending
- 2020-02-05 WO PCT/US2020/016820 patent/WO2020163493A2/en not_active Ceased
- 2020-02-05 BR BR112021015466-3A patent/BR112021015466A2/pt not_active IP Right Cessation
- 2020-02-05 CN CN202080027379.9A patent/CN114007607A/zh active Pending
- 2020-02-05 US US17/428,867 patent/US20220401404A1/en not_active Abandoned
- 2020-02-05 CA CA3129050A patent/CA3129050A1/en active Pending
- 2020-02-05 MX MX2021009413A patent/MX2021009413A/es unknown
- 2020-02-05 EP EP20753139.3A patent/EP3930711A4/en not_active Withdrawn
- 2020-02-05 AU AU2020219140A patent/AU2020219140A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gomathi et al. | Drug studies on Rett syndrome: from bench to bedside | |
| Trotti | Restless legs syndrome and sleep-related movement disorders | |
| EKBOM et al. | Muscular affections in chronic alcoholism | |
| Lasser et al. | Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone | |
| Lapid et al. | Efficacy, safety, and tolerability of armodafinil therapy for hypersomnia associated with dementia with Lewy bodies: a pilot study | |
| JP2022523919A5 (https=) | ||
| Comella | Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview | |
| MacDonald et al. | A novel phosphodiesterase type 4 inhibitor, HT-0712, enhances rehabilitation-dependent motor recovery and cortical reorganization after focal cortical ischemia | |
| Johnson et al. | Decreased brain reward function during nicotine withdrawal in C57BL6 mice: evidence from intracranial self-stimulation (ICSS) studies | |
| Esmail | The diagnosis and management of Parkinson’s disease | |
| Calne | Parkinsonism: Clinical and neuropharmacologic aspects | |
| Pujia et al. | Cutaneous silent period in hand muscles is lengthened by tramadol: Evidence for monoaminergic modulation? | |
| Baba et al. | Anti-cholinergics for axial symptoms in Parkinson's disease after subthalamic stimulation | |
| Sechi et al. | Ceftriaxone has a therapeutic role in Alexander disease | |
| Fleming et al. | P. 3. c. 073 Effects of asenapine on cognitive function in acute schizophrenia: a placebo-and risperidone-controlled trial | |
| Pae et al. | Switching to quetiapine in patients with acute mania who were intolerant to risperidone | |
| Roze et al. | Update on sleep disorders in advanced Parkinson’s disease: a narrative review | |
| Freeman et al. | ICU management of patients with Parkinson's disease or Parkinsonism | |
| Liu et al. | Associations between peripheral nerve stimulation and cognitive performance: insights from healthy individuals and various disease pathologies | |
| Šonka et al. | Management of restless legs syndrome by the partial D2-agonist terguride | |
| CN110461330A (zh) | 用于治疗亨廷顿氏病的PPARγ激动剂 | |
| Roggeman et al. | Constrained-induced dysarthria therapy: case report | |
| JP2014505074A5 (https=) | ||
| Singh et al. | A case of drug induced dizziness in a patient on anti-Parkinson drugs | |
| Kovalzon et al. | The neurochemistry of the sleep-wakefulness cycle and Parkinson’s disease |